1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
    Journal Article

    Wells, D. K.; van Buuren, M. M.; Dang, K. K.; Hubbard-Lucey, V. M.; Sheehan, K. C. F.; Campbell, K. M.; Lamb, A.; Ward, J. P.; Sidney, J.; Blazquez, A. B.; more...
    Cell (2020)

    Fulltext@MSK | Save
  • PD-L1 blockade therapy: Location, location, location
    Editorial

    Brown, C. C.; Wolchok, J. D.
    Cancer Cell (2020)

    Fulltext@MSK | Save
  • CheckMate 067: Long-term outcomes in patients with mucosal melanoma
    Meeting Abstract

    Shoushtari, A. N.; Wagstaff, J.; Ascierto, P. A.; Butler, M. O.; Lao, C. D.; Marquez-Rodas, I.; Chiarion-Sileni, V.; Dummer, R.; Ferrucci, P. F.; Lorigan, P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
    Meeting Abstract

    Khan, S.; Lutzky, J.; Shoushtari, A. N.; Jeter, J. M.; Chiuzan, C.; Sender, N.; Blumberg, L. E.; Nesson, A.; Singh-Kandah, S. V.; Hernandez, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Holm, J. S.; Funt, S. A.; Bjerregaard, A. M.; Reading, J. L.; Maher, C. A.; Regazzi, A. M.; Wong, P.; Al-Ahmadie, H.; Overgaard, N. H.; Tamhane, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The nature and management of acquired resistance to PD1-based therapy in melanoma
    Meeting Abstract

    Hepner, A.; Versluis, J. M.; Gerard, C. L.; Brown, L. J.; Wallace, R.; Bhave, P.; Jansen, Y.; Klein, O.; Warner, A. B.; Mangana, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)
    Meeting Abstract

    Dummer, R.; Sandhu, S. K.; Miller, W. H.; Butler, M. O.; Blank, C. U.; Muñoz-Couselo, E.; Burris, H. A. 3rd; Postow, M. A.; Chmielowski, B.; Middleton, M. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy
    Meeting Abstract

    Da Silva, I. P.; Ahmed, T.; Lo, S.; Reijers, I. L. M.; Weppler, A.; Warner, A. B.; Patrinely, J. R.; Serra-Bellver, P.; Lebbe, C.; Mangana, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save